Citations

Clear

6273 citation(s) found for "To, Andrew".

Market-Level Features May Influence a Hospital’s Decision to Perform Robotic Radical Cystectomy in Florida
Qosja, Neda, Spaulding, Aaron , Zganjar, Andrew , Borkar, Shalmali R. , Pathak, Ram , Lyon, Timothy D. , Zganjar, Andrew J., Lyon, Timothy D , Spaulding, Aaron , Colibaseanu, Dorin

Mayo Clinic

Urology Practice | March 28, 2025 | Volume: 12 | Issue: 4 | Pages: 391-400

10.1097/upj.0000000000000816 | PMID 40152667 Get It

HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era
Okcu, Izel, Nowakowski, Grzegorz S. , Amengual, Jennifer E. , Ross, Che, Bock, A., Okcu, Izel , Pierce, Andrew L., Tolu, Seda , Graber, Jerome J. , Hu, Boyu , Ermann, Daniel A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7347 Get It

Nature's Cystenterostomy: Spontaneous Pancreaticocolonic Fistulae Formation in Infected Pancreatic Walled-Off Necrosis
Gala, Khushboo, Gala, Khushboo , Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | March 28, 2025 | Volume: 120 | Issue: 11 | Pages: 2471-2471

10.14309/ajg.0000000000003437 | PMID 40146018 Get It

Cyst Detection Ratio, a Quality Indicator for EUS-Based Pancreatic Cancer Screening: A Systematic Review and Meta-Analysis to inform Quality Improvement Benchmark
Chhoda, Ankit , Grimshaw, Andrew, Sawhney, Mandeep , Woodbine, Maria Jose Hernandez , Magahis, Patrick T. , Manoj, Matthew Antony , Grimshaw, A

Mayo Clinic

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1806286 Get It

Surveillance Potential of Chronic Pancreatitis-Like Lesions Among High-Risk Individuals: A Systematic Review and Meta-analysis
Chhoda, Ankit , Dhar, Jyoti , Grimshaw, Andrew, Sawhney, Mandeep , Magahis, Patrick T. , Mills, K, Dhar, J, Grimshaw, A

Mayo Clinic

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1806269 Get It

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Borate, Uma , Pugh, Kelly , Waller, Allyson, Welkie, Rina Li , Huang, Ying , Stahl, Maximilian , Platzbecker, Uwe , Wei, Andrew H. , Buckstein, Rena , Hasserjian, Robert P. , Fenaux, Pierre , Sallman, David A. , Nimer, Stephen D. , Little, Richard F. , Garcia‐Manero, Guillermo , Odenike, Olatoyosi, Kim, Tae Kon , Greenberg, Peter L. , Xu, Mina L. , Patnaik, Mrinal M. , Padron, Eric , Gore, Steven D. , Churpek, Jane E. , Bennett, John M., Brunner, Andrew M. , Zeidan, Amer M., Zeidan, Amer M. , Platzbecker, Uwe , Sekeres, Mikkael A , Wei, Andrew H , Roboz, Gail J , Loghavi, Sanam , Hasserjian, Robert P , Sallman, David A , Hourigan, Christopher S , Della Porta, Matteo Giovanni , Little, Richard F , Santini, Valeria , Taylor, Justin , Kim, Tae Kon , Halene, Stephanie , Komrokji, Rami S , Griffiths, Elizabeth A. , Greenberg, Peter L , Xie, Zhuoer , Sanz, Guillermo F , Patnaik, Mrinal , Carraway, Hetty E. , Boultwood, Jacqueline , Daver, Naval , Zeidan, Amer M , Churpek, Jane E , Bewersdorf, Jan Philipp , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Roboz, Gail J. , Savona, Michael R. , Loghavi, Sanam , Hourigan, Christopher S. , Santini, Valeria , Efficace, Fabio , Odenike, Olatoyosi , Komrokji, Rami S. , Xie, Zhuoer , Bejar, Rafael , Sanz, Guillermo , Figueroa, María E. , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Boultwood, Jacqueline , Daver, Naval , Majeti, Ravindra , List, Alan F. , Brunner, Andrew M., Churpek, Jane

Mayo Clinic

Blood | March 27, 2025 | Volume: 145 | Issue: 13 | Pages: 1369-1381

10.1182/blood.2023023717 | PMID 40146152 Get It

Abstract Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.
Multicenter analysis of flow diversion for recurrent/persistent intracranial aneurysms after stent-assisted coiling
Salem, Mohamed M. , Helal, Ahmed , Gajjar, Avi A. , Sioutas, Georgios S. , Heiferman, Daniel M. , Lylyk, Iván , Levine, Alex, Salih, Mira , Abbas, Rawad , Saber, Hamidreza , Lanzino, Giuseppe, Brinjikji, Waleed , Tanweer, Omar , Spiotta, Alejandro M , Park, Min S. , Dumont, Aaron S. , Kim, Louis J. , Kan, Peter , Wolfe, Stacey Q , Raz, Eytan , Shapiro, Maksim , Siddiqui, Adnan H. , Ares, William J. , Ogilvy, Christopher S. , Srinivasan, Visish M. , Starke, Robert M., Ducruet, Andrew F. , Tjoumakaris, Stavropoula , Jankowitz, Brian T. , Albuquerque, Felipe C , Nelson, Peter Kim , Riina, Howard A. , Lylyk, Pedro , Jabbour, Pascal , Burkhardt, Jan Karl, Heiferman, Daniel M , Lylyk, Ivan , Desai, Sohum , Borg, Nicholas , Brinjikji, Waleed , Spiotta, Alejandro M , Arthur, Adam Stephen , Levitt, Michael R , Kan, Peter , Hassan, Ameer E , Wolfe, Stacey Quintero , Raz, Eytan , Siddiqui, Adnan H , Ares, William J , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Jankowitz, Brian , Albuquerque, Felipe C , Jabbour, Pascal , Burkhardt, Jan‐Karl , Naamani, Kareem El , Renieri, Leonardo , Monteiro, Andre , Abdelsalam, Ahmed, Catapano, Joshua S , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hassan, Ameer E , Limbucci, Nicola , Colby, Geoffrey P. , Hanel, Ricardó A. , Levy, Elad I. , Thomas, Ajith J , Lopes, Demetrius K.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 27, 2025 | Volume: 18 | Issue: 2 | Pages: 324-331

10.1136/jnis-2024-022422 | PMID 40139781 Get It

Background Flow-diverter stents (FDS) have become the standard of care for a wide range of intracranial aneurysms, but their efficacy/safety in the context of recurrent/recanalized aneurysms following stent-assisted coiling (SAC) is not well established. We evaluate the outcomes of FDS retreatment in a large multicenter cohort. Methods We retrospectively analyzed data from 118 patients across 22 institutions who underwent FDS retreatment for recurrent/persistent aneurysms after SAC (2008–22). The primary outcome was angiographic occlusion status at last follow-up, categorized as complete (100%), near-complete (90–99%), or incomplete (<90%) occlusion. Secondary outcomes included procedural complications and clinical outcomes measured by the modified Rankin Scale (mRS). Results A total of 118 patients (median age 57, 74.6% female) with median follow-up of 15.3 months were identified. Complete occlusion was achieved in 62.5% and near-complete occlusion in 25%. FDS deployment within the pre-existing stent was successful in 98.3% of cases. Major complications occurred in 3.4% of cases, including postoperative aneurysmal rupture with resultant mortality (1.6%) and thromboembolic events with long-term disability (1.6%). Favorable clinical outcomes (mRS 0–2) were observed in 95.1% of patients. Wider aneurysm neck diameter was a significant predictor of incomplete occlusion (adjusted OR (aOR) 1.23 per mm, P=0.044), with male sex trending towards association with non-occlusion (aOR 3.2, P=0.07), while baseline hypertension was associated with complete occlusion (aOR 0.32, P=0.048). Conclusions FDS treatment for recurrent/residual aneurysms after SAC represents a viable treatment option for these challenging cases with acceptable safety and reasonable occlusion rates, although lower than de novo FDS occlusion rates.
2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Bartels, Christie M. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Fava, Andrea , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | March 26, 2025 | Volume: 77 | Issue: 9 | Pages: 1045-1065

10.1002/acr.25528 | PMID 40127995 Get It

Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis. Methods The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response. Conclusion This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
26 Evaluating AI models trained with varying amounts of expert feedback for chronic graft-versus-host disease skin assessment in photos of patients with diverse skin tones
McNeil, Andrew , Parks, Kelsey , Pogharian, Michael, Pavletic, Steven Z. , Dawant, Benoît M. , McNeil, Andrew, Cowen, Edward W , Lehman, Julia S. , Lee, Stephanie J. , Tkaczyk, Eric R.

Mayo Clinic

Journal of Clinical and Translational Science | March 25, 2025 | Volume: 9 | Issue: s1 | Pages: 9-10

10.1017/cts.2024.717 Get It

Objectives/Goals: Manual skin assessment in chronic graft-versus-host disease (cGVHD) can be time consuming and inconsistent (>20% affected area) even for experts. Building on previous work we explore methods to use unmarked photos to train artificial intelligence (AI) models, aiming to improve performance by expanding and diversifying the training data without additional burden on experts. Methods/Study Population: Common to many medical imaging projects, we have a small number of expert-marked patient photos (N = 36, n = 360), and many unmarked photos (N = 337, n = 25,842). Dark skin (Fitzpatrick type 4+) is underrepresented in both sets; 11% of patients in the marked set and 9% in the unmarked set. In addition, a set of 20 expert-marked photos from 20 patients were withheld from training to assess model performance, with 20% dark skin type. Our gold standard markings were manual contours around affected skin by a trained expert. Three AI training methods were tested. Our established baseline uses only the small number of marked photos (supervised method). The semi-supervised method uses a mix of marked and unmarked photos with human feedback. The self-supervised method uses only unmarked photos without any human feedback. Results/Anticipated Results: We evaluated performance by comparing predicted skin areas with expert markings. The error was given by the absolute difference between the percentage areas marked by the AI model and expert, where lower is better. Across all test patients, the median error was 19% (interquartile range 6 – 34) for the supervised method and 10% (5 – 23) for the semi-supervised method, which incorporated unmarked photos from 83 patients. On dark skin types, the median error was 36% (18 – 62) for supervised and 28% (14 – 52) for semi-supervised, compared to a median error on light skin of 18% (5 – 26) for supervised and 7% (4 – 17) for semi-supervised. Self-supervised, using all 337 unmarked patients, is expected to further improve performance and consistency due to increased data diversity. Full results will be presented at the meeting. Discussion/Significance of Impact: By automating skin assessment for cGVHD, AI could improve accuracy and consistency compared to manual methods. If translated to clinical use, this would ease clinical burden and scale to large patient cohorts. Future work will focus on ensuring equitable performance across all skin types, providing fair and accurate assessments for every patient.
An advanced diagnostic imaging tool to enhance clinical decision-making and wound healing
Serena, Thomas E , Couch, Amy L, Wahab, Naz , Alonso, Misael, Kapp, Daniel S. , Johnson, Martin L., Gitterle, Marcus, Serena, Thomas , Tettelbach, William H , Rader, Andrew J. , Alonso, Misael, Kelso, Martha R

Mayo Clinic

Journal of Wound Care | March 22, 2025 | Volume: 34 | Issue: 4 | Pages: 272-277

10.12968/jowc.2025.0104 | PMID 40227918 Get It